Critical Analysis: Titan Pharmaceuticals (NASDAQ:TTNP) vs. Lexeo Therapeutics (NASDAQ:LXEO)

Titan Pharmaceuticals (NASDAQ:TTNP) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Institutional & Insider Ownership

31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 24.9% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Titan Pharmaceuticals and Lexeo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Pharmaceuticals	-2,014.71%	-165.90%	-105.75%
Lexeo Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Titan Pharmaceuticals and Lexeo Therapeutics’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Pharmaceuticals	$180,000.00	36.69	-$5.57 million	($8.20)	-0.89
Lexeo Therapeutics	$650,000.00	619.97	-$66.39 million	N/A	N/A

Titan Pharmaceuticals has higher earnings, but lower revenue than Lexeo Therapeutics.

Analyst Ratings

This is a summary of recent ratings and target prices for Titan Pharmaceuticals and Lexeo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Pharmaceuticals	0	0	0	0	N/A
Lexeo Therapeutics	0	0	6	0	3.00

Lexeo Therapeutics has a consensus price target of $20.80, indicating a potential upside of 70.07%. Given Lexeo Therapeutics’ higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Titan Pharmaceuticals.

Summary

Lexeo Therapeutics beats Titan Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.